Similar Articles
501 Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells
502 Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma
503 Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma
504 High expression of protein phosphatase 2 regulatory subunit B'' alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation
505 Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges
506 Worldwide management of hepatocellular carcinoma during the COVID-19 pandemic
507 Application of radiomics in hepatocellular carcinoma: A review
508 Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?
509 Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements
510 High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA